The results of the Phase II clinical study announced at the 2022 WCLC Conference showed that pembrolizumab combined with Itacitinib (INCB039110, a JAK inhibitor) in the first‐line treatment of metastatic NSCLC with PD‐L1 ≥ 50% had a 12‐week ORR of 62%, and the mPFS was 23.4 months, achieving a meaningful and sustained ORR, which is expected to become a treatment trend in the future. The gene discussed is CD274; the disease is non-small cell lung carcinoma.